Curetis (CURE-NL): Focus on US launch

Dow Jones received a payment from EQS/DGAP to publish this press release.

goetzpartners securities Limited 
Curetis (CURE-NL): Focus on US launch 
 
23-Nov-2017 / 16:52 GMT/BST 
 
*This equity research note was formally published on 17th November 2017 at 
5.00am.* 
 
*Curetis (CURE-NL): Focus on US launch* 
 
*Recommendation: OUTPERFORM* 
*Target price: EUR10.00* 
*Current price (as at 17th Nov 2017): EUR3.75* 
 
Sluggish EU sales growth and slippage in the installed base target into 
Q1/2018 were sure to disappoint. While exact timing can never be assured, we 
remain confident that FDA approval will take place within the next month or 
two. While it is always possible that approval may drop into next year, the 
2018 US launch of the Unyvero platform remains the major Curetis driver. We 
believe clear differences between the markets should see significantly faster 
growth in the US compared with Europe. We remain optimistic that the first US 
launch and the prospect of a pipeline of additional US cartridge approvals 
should have a positive impact on both installed base, cartridge volumes and 
sales during 2018. China remains a substantial opportunity for Unyvero, as 
well as strategic deal flow through the Ares Genetics subsidiary. Given the 
anticipated upside, we remain positive despite European delays. The current 
stock weakness looks substantially over done and is a good entry point for 
investors. We maintain and reiterate our OUTPERFORM recommendation and EUR10 
target price. 
 
*Europe disappoints* - Installations and sales continue to lag expectations in 
Europe. While the company is hopeful that the appointment of Riwat Lim from 
QIAGEN will invigorate progress, the company will need to show it can speed 
and expand the conversion of current demonstration and evaluation sites into 
real sales. 
 
*Brighter prospects in the US -* We remain as confident as we can be that FDA 
approval will take place shortly. Better funded and less fragmented, the US 
healthcare market is generally more receptive to innovation than Europe. With 
US hospitals increasingly penalised for poor infection control and subjected 
to antibiotic stewardship guidelines (20% - 50% of US patients receive 
antibiotics that they don't need) and the threat of litigation for 
misdiagnosis, commercial and regulatory incentives to adopt rapid infectious 
disease diagnostics in the US are building. This is reflected in the feedback 
from US physicians we have spoken to. This together with a pipeline of new 
panels, should drive adoption of the Curetis Unyero platform during 2018 
following FDA approval. 
 
*Further upside from China and other deal flow -* Unyvero continues to 
progress towards regulatory submission in China. The recent agreement with MGI 
in China has opened up the prospect of broader strategic collaboration and 
highlights the potential for deal flow through the Ares Genetics antibiotic 
resistance subsidiary in China and beyond. 
 
*Funded to inflection -* Although given the European delays, Curetis may 
struggle to achieve our current EUR2.5m top-line estimate for 2017, YE cash 
should be in-line with our expectations (see FDA approval major catalyst in H2 
[1]) and, with a further EUR15m to draw down from the EIB, sufficient to take 
the company through the anticipated inflection points and well-placed to raise 
additional capital thereafter. 
 
*Positive on the upside -* Retaining our estimates beyond 2017 (see FDA 
approval major catalyst in H2 [1]), we are optimistic for significant upside 
during 2018. We maintain and reiterate our OUTPERFORM recommendation and EUR10 
target price. 
 
Click here for full PDF version [2] 
 
goetzpartners Corporate Research | Research Team 
Dr. Chris Redhead | Analyst 
 
goetzpartners Corporate Research 
goetzpartners securities Limited 
The Stanley Building, 7 Pancras Square, London, N1C 4AG, England, UK. 
T [phone] | [e-mail] / 
[e-mail] 
 
www.goetzpartnerssecurities.com [3] / www.goetzpartners.com [4] 
 
Registered in England No. 04684144. 
Managing Directors: Dr Stephan Goetz, Martin Brunninger and Ulrich Kinzel. 
 
To be added, or to change your subscriptions or to be removed / unsubscribed 
entirely from our CRM, please e-mail: [e-mail] 
 
This research report is intended for use only by persons who qualify as 
professional investors or eligible counterparties (institutional investors) in 
the applicable jurisdiction, and not by any private individuals or other 
persons who qualify as retail clients. 
 
This communication (including any links and or attachments) from goetzpartners 
securities Limited ("GPSL") is confidential and may contain information which 
is proprietary, privileged or otherwise legally protected against unauthorised 
use or disclosure. If you receive this communication in error or are not the 
intended recipient of this communication, please delete and destroy all copies 
in your possession, notify the sender that you have received this 
communication, and note that any review or dissemination of, or the taking of 
any action in reliance on this communication is expressly prohibited. GPSL 
shall not be liable for the improper or incomplete transmission of the 
information contained in this communication nor for any delay in its receipt 
or damage to your system. GPSL does not guarantee that the integrity of this 
communication has been maintained nor that this communication is free of 
viruses, interceptions or interference and makes no warranties in relation to 
these matters. This is not an offer or a solicitation to buy or sell 
securities or investment products, or an official confirmation. GPSL [5] is 
authorised and regulated by the Financial Conduct Authority of the United 
Kingdom (Firm Reference Number: 225563). 
 
GPSL publishes both non-independent (corporate sponsored) and investment 
research. 
 
Click on the following hyperlink for our Research Library: GPSL Equity 
Research Library [6] 
 
GPSL equity research publications are also available and accessible on the 
following aggregators (for Institutional Use Only): AlphaSense, Bloomberg 
(GOET), Capital IQ, EQS, FACTSET, RNS Reach and Thomson Reuters. 
 
If you cannot click on the above hyperlink please copy the below link and 
paste it into your browser for the full pdf version of the equity research 
report. 
 
https://gp.bluematrix.com/sellside/EmailDocViewer?encrypt=660933b6-c64b-41a8-a 
e94-fa6191995569&mime=pdf&co=gp&id=[e-mail]&source=library 
View [7] 
 
Dissemination of a FINANCIAL NEWS, transmitted by EQS Group. 
The issuer is solely responsible for the content of this announcement. 
End of Announcement - EQS News Service 
 
632337 23-Nov-2017 
 
 
1: http://public-cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=6de1df868785da82749ce0f7ad487276&application_id=632337&site_id=vwd&application_name=news 
2: http://public-cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=579e73033a5a4b9905902512c2a498f0&application_id=632337&site_id=vwd&application_name=news 
3: http://public-cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=750ca54579c5d5447638f7f35718f4d1&application_id=632337&site_id=vwd&application_name=news 
4: http://public-cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=f8cefacf98ae99af351300c1a543fffb&application_id=632337&site_id=vwd&application_name=news 
5: http://public-cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=ba4d174d6cc17a15461e9920a97cb6e6&application_id=632337&site_id=vwd&application_name=news 
6: http://public-cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=a8a38ea79831272865b5aae2e3600818&application_id=632337&site_id=vwd&application_name=news 
7: http://public-cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=6a281b3e0825c054dc6def19f0fd0153&application_id=632337&site_id=vwd&application_name=news 
 

(END) Dow Jones Newswires

November 23, 2017 11:52 ET (16:52 GMT)